Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Endotoxin/LPS
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseEndotoxin/LPSBALB/cMalen = n = 4 to 8 mice per group for BAL endpoints and n = 6 for B…Anti-G-CSF antibody intraperitoneal in 100 microlitres PBS; dexamethasone intraperitoneal in 100 microlitres PBS; LPS intratracheal in 100 microlitres PBSAnti-G-CSF antibody 250 micrograms/kg; dexamethasone 2.5 mg…Both dexamethasone and anti-G-CSF antibody given 6 hours after the LPS challeng…
Model: Intratracheal lipopolysaccharide (1 mg/kg) induced acute lung injury
Dexamethasone alone suppressed BAL TNF and IL-6 but did not reduce LPS-induced G-CSF, BAL neutrophils, BAL total protein or lung injury, and increased airway neutrophil numbers at 24 hours. Adding the anti-G-CSF neutralising antibody allowed dexamethasone to lower BAL G-CSF and neutrophil numbers a…
Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.